EvaluatePharma’s report (#msg-132374740) has ABBV/ENTA’s Maviret (G/P) outselling GILD’s Vosevi (SOF/VEL/VOX) in 2022 by 10%, FWIW. (See table on page 34 of full report.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.